Skip to main content
Gentian Diagnostics ASA logo

Gentian Diagnostics ASA — Investor Relations & Filings

Ticker · GENT ISIN · NO0010748866 LEI · 5967007LIEEXZXHNM861 OL Manufacturing
Open in API
Filings indexed 466 across all filing types
Latest filing 2026-04-13 AGM Information
Country NO Norway
Listing OL GENT

About Gentian Diagnostics ASA

https://www.gentian.com/

Gentian Diagnostics ASA is a medical diagnostics company that develops, manufactures, and markets innovative in vitro diagnostic (IVD) reagents. The company specializes in turbidimetric immunoassays designed for open clinical chemistry platforms, aiming to enhance laboratory efficiency and support better clinical treatment decisions. Its portfolio and pipeline of diagnostic tests address biomarkers in high-impact medical areas, including kidney disease, cardiac disease, inflammation, and infection. Key products include assays for Cystatin C, NGAL, and Calprotectin. In addition to its human diagnostics portfolio, the company provides diagnostic solutions for the veterinary market. Gentian serves a global customer base through original equipment manufacturer (OEM) partners, distributors, and healthcare providers.

Recent filings

Filing Released Lang Actions
Gentian Diagnostics: Notice of annual general meeting - Attachment: GDASA AGM 2026 05 05.pdf
AGM Information Classification · 100% confidence The document is titled 'Gentian Diagnostics ASA Notice of Annual General Meeting' and contains detailed agenda items for the AGM scheduled on 5 May 2026. It includes election of board members, approval of financial statements, dividend distribution, remuneration proposals, and authorizations related to share capital and share buybacks. The document is a notice convening the AGM and outlining the agenda and proposals to be voted on, rather than the actual annual report or financial statements themselves. It references the annual report and remuneration report as available on the company's website but does not contain the reports themselves. The document is lengthy (15,000 characters) but is clearly a meeting notice and agenda, not a full report or transcript. Therefore, the appropriate classification is AGM Information (AGM-R).
2026-04-13 Norwegian
Gentian Diagnostics: Notice of annual general meeting
Proxy Solicitation & Information Statement Classification · 75% confidence The document is a statutory notice of an upcoming Annual General Meeting, providing shareholders with meeting details and enclosing appendices (likely the proxy materials and information on resolutions). This matches the definition of Proxy Solicitation & Information Statement (PSI), which covers materials sent to shareholders to inform and solicit votes for meetings.
2026-04-13 English
Gentian Diagnostics ASA - Registration of share capital increase
Share Issue/Capital Change Classification · 89% confidence The document announces the registration of a share capital increase related to an Employee Share Purchase Program, providing new share capital and share count details. This is clearly an announcement of a capital change (share issue). It does not fit proxies, dividends, or regulatory fallback categories, but matches ‘Share Issue/Capital Change’ (SHA).
2026-04-10 English
Gentian Diagnostics: Annual report 2025 - Attachment: GDASA annual report 2025.pdf
Annual Report Classification · 100% confidence The document is titled '2025 Annual report' and contains comprehensive sections including a letter from the CEO, key financial figures, board of directors report, corporate governance, ESG report, and financial statements. It covers the full fiscal year 2025 performance, which aligns with the definition of an Annual Report (10-K). FY 2025
2026-03-20 English
Gentian Diagnostics: Annual report 2025 - Attachment: 5967007LIEEXZXHNM861-2025-12-31-1-en.zip
Annual Report Classification · 100% confidence The document is a detailed report containing comprehensive financial data, including revenue, EBITDA, profit margins, cash flow, and equity ratios for multiple years. It includes a letter from the CEO, a board of directors report, corporate governance report, ESG report, and full financial statements for the year 2025. The presence of extensive financial statements, management commentary, and detailed operational and strategic information indicates this is a full annual report. The document length is substantial (15,000 characters), and it is not merely an announcement or a certification. Therefore, it fits the definition of an Annual Report (10-K). FY 2025
2026-03-20 English
Gentian Diagnostics: Annual report 2025
Report Publication Announcement Classification · 100% confidence The document is very short (514 characters) and explicitly states that the company has 'today published its annual report' and that the report is 'attached to this stock exchange notice'. According to the 'Menu vs Meal' rule, an announcement stating that a report has been published or is attached is classified as a Report Publication Announcement (RPA), not the report itself.
2026-03-20 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.